Zobrazeno 1 - 10
of 14
pro vyhledávání: '"M-A Rémillard"'
Autor:
Frédéric Massicotte, Edith Villeneuve, Paul Haraoui, D. Sauvageau, Louis Bessette, Loïc Choquette Sauvageau, Jean-Pierre Raynauld, Denis Choquette, Jean-Pierre Pelletier, L. Coupal, Isabelle Ferdinand, M.-A. Rémillard
Publikováno v:
SATURDAY, 15 JUNE 2019.
Background Tofacitinib (TOFA), a targeted synthetic DMARD, has been approved for the treatment of rheumatoid arthritis (RA) in Canada since April 2014. This oral agent preferentially inhibits signalling by cytokine receptors associated with JAK1 and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::21136946ab3547d40432270da263d13d
https://doi.org/10.1136/annrheumdis-2019-eular.2823
https://doi.org/10.1136/annrheumdis-2019-eular.2823
Autor:
Edith Villeneuve, Jean-Pierre Raynauld, Denis Choquette, M.-A. Rémillard, D. Sauvageau, Loïc Choquette Sauvageau, Jean-Pierre Pelletier, Paul Haraoui, Isabelle Ferdinand, L. Coupal, Frédéric Massicotte, Louis Bessette
Publikováno v:
Poster Presentations.
Background: Anemia is a common feature of RA. Prior to the appearance of biologic treatments, improvement of hemoglobin (Hb) levels was unusual and inconsistent. With better control of the inflammatory process with cytokine inhibitors, it has been sh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4ce73641c2c9cdf78e138a589fb386f0
https://doi.org/10.1136/annrheumdis-2019-eular.4161
https://doi.org/10.1136/annrheumdis-2019-eular.4161
Autor:
Louis Bessette, Edith Villeneuve, Jean-Pierre Pelletier, L. Coupal, D. Sauvageau, M.-A. Rémillard, Jean-Pierre Raynauld, Isabelle Ferdinand, Denis Choquette, Paul Haraoui, Loïc Choquette Sauvageau, Frédéric Massicotte
Publikováno v:
SATURDAY, 15 JUNE 2019.
Background Tofacitinib (TOFA), a targeted synthetic DMARD, has been approved for the treatment of rheumatoid arthritis (RA) in Canada since April 2014. This oral agent preferentially inhibits signalling by cytokine receptors associated with JAK1 and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b725d3cf0a94276a2b4d1795b9402460
https://doi.org/10.1136/annrheumdis-2019-eular.3110
https://doi.org/10.1136/annrheumdis-2019-eular.3110
Autor:
Louis Bessette, Edith Villeneuve, Frédéric Massicotte, Jean-Pierre Raynauld, Denis Choquette, D. Sauvageau, L. Coupal, Loïc Choquette Sauvageau, Jean-Pierre Pelletier, M.-A. Rémillard, Isabelle Ferdinand, Paul Haraoui
Publikováno v:
Abstracts accepted for Publication.
Background Secukinumab (SECU) is a human IgG1κ monoclonal antibody that binds to the protein interleukin-17A approved for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis (PsA). Recently presented data suggest that combina
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20e9af90cade843f33745672dc114afc
https://doi.org/10.1136/annrheumdis-2019-eular.3132
https://doi.org/10.1136/annrheumdis-2019-eular.3132
Autor:
J.-P. Pelletier, Louis Bessette, D. Sauvageau, L. Coupal, Edith Villeneuve, Isabelle Ferdinand, J.-P. Raynauld, Boulos Haraoui, Denis Choquette, Frédéric Massicotte, M.-A. Rémillard, L. Choquette Sauvageau
Publikováno v:
Annals of the Rheumatic Diseases. 79:1467.1-1467
Background:Since the introduction of biologic agents around the turn of the century, the scientific evidence shows that the majority of agents, independent of the therapeutic target, have a better outcome when used in combination with methotrexate (M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d7bcddd2551208258928d8bef050eb68
https://doi.org/10.1136/annrheumdis-2020-eular.2479
https://doi.org/10.1136/annrheumdis-2020-eular.2479
Autor:
J.-P. Raynauld, Roelien Postema, D. Sauvageau, M Mtibaa, Frédéric Massicotte, J.-P. Pelletier, M-A Rémillard, E Muratti, Evo Alemao, Boulos Haraoui, Louis Bessette, L. Coupal, Έ. Villeneuve, A Turcotte, Denis Choquette
Publikováno v:
Abstracts Accepted for Publication.
Background In the absence of biomarkers predicting response to a specific therapy, the choice of second biologic is based mostly on habit and availability of an alternative agent. Traditionally, a second anti-TNF was the preferred option, but recent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c19b7f8a057dab3945167227e4eb72b
https://doi.org/10.1136/annrheumdis-2017-eular.2379
https://doi.org/10.1136/annrheumdis-2017-eular.2379
Autor:
M Mtibaa, E Muratti, J.-P. Pelletier, Frédéric Massicotte, J.-P. Raynauld, Roelien Postema, Boulos Haraoui, M-A Rémillard, Evo Alemao, L. Coupal, Louis Bessette, Έ. Villeneuve, D. Sauvageau, A Turcotte, Denis Choquette
Publikováno v:
Poster Presentations.
Background Sustainability of treatment is important to consider when selecting a therapy for chronic conditions such as RA. Sustainability is a useful clinical marker for both long-term efficacy and safety. A recently published randomized controlled
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::daeed4a31ad2ab389bacb20acc08a961
https://doi.org/10.1136/annrheumdis-2017-eular.2326
https://doi.org/10.1136/annrheumdis-2017-eular.2326
Autor:
D Choquette, L Bessette, B Haraoui, F Massicotte, J-P Pelletier, J-P Raynauld, M-A Rémillard, D Sauvageau, A Turcotte, Έ Villeneuve, L Coupal
Publikováno v:
Poster Presentations.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc50e3cee0c334cd4d5278f39b39ec7f
https://doi.org/10.1136/annrheumdis-2017-eular.6361
https://doi.org/10.1136/annrheumdis-2017-eular.6361
Autor:
Frédéric Massicotte, J.-P. Raynauld, J.-P. Pelletier, Boulos Haraoui, Denis Choquette, M.-A. Rémillard, J. Brown, L. Coupal, Louis Bessette, Έ. Villeneuve, D. Sauvageau
Publikováno v:
Annals of the Rheumatic Diseases. 75:471.3-472
Background Herpes Zoster (HZ) is caused by the reactivation of the varicella zoster virus. It is more prevalent in older populations. Post-herpetic neuralgia, defined as pain lasting longer than 90 days post-eruption, is the most common serious compl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f3e78f7fd273ac6fdbd5bc5839f24c50
https://doi.org/10.1136/annrheumdis-2016-eular.3567
https://doi.org/10.1136/annrheumdis-2016-eular.3567
Autor:
J. Brown, Frédéric Massicotte, L. Coupal, J.-P. Pelletier, Έ. Villeneuve, Louis Bessette, D. Sauvageau, Boulos Haraoui, Denis Choquette, J.-P. Raynauld, M.-A. Rémillard
Publikováno v:
Annals of the Rheumatic Diseases. 75:190.1-190
Background The order of use of biologic agents after failing a TNF inhibitor remains a question for debate. Phase III trial data in TNF-IR patients show comparable efficacy results across biologic agents, and limited head-to-head studies have been pu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db3868aa04dc02e9075715d8e63a665e
https://doi.org/10.1136/annrheumdis-2016-eular.3628
https://doi.org/10.1136/annrheumdis-2016-eular.3628